Pure Global
NCT06344026

Phase 1/2a Study of ANPD001 in Parkinson Disease

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Aspen Neuroscience·Phase 1·ClinicalTrials.gov·biologicalEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
ANPD001
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Aspen Neuroscience
Location
Tucson,La Jolla,Orange,San Francisco,Manhasset, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jan 23, 2024
End date
Apr 30, 2030
Enrollment
9 participants
Primary outcome

Incidence and severity of treatment emergent adverse events (Safety and Tolerability)

Summary

This clinical trial is designed to test the safety and tolerability of injecting ANPD001
 cells that will mature into dopamine-producing cells into the brain of participants with
 Parkinson Disease. All participants will have ANPD001 cells manufactured from their own
 previously collected cells.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06344026
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06344026 through Pure Global AI's free database. This Phase 1 trial is sponsored by Aspen Neuroscience and is currently Enrolling by invitation. The study focuses on Parkinson Disease. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.